Results 171 to 180 of about 1,502,489 (240)

Post-vitrectomy Macular Edema: Shedding Light on Incidence and Risk Factors. [PDF]

Ophthalmol Ther
Verplaetse V, van Dijk EHC, Faridpooya K.   +2 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

The Boston Retinal Implant

2016
The Boston Retinal Implant Project has developed a subretinal, hermetically-enclosed, chronically-implantable vision prosthesis to restore some useful vision to people with degenerative retinal diseases, especially retinitis pigmentosa and age-related macular degeneration.
Shawn K. Kelly, Joseph Rizzo
openaire   +2 more sources

Update on Retinal Prosthetic Research: The Boston Retinal Implant Project

Journal of Neuro-Ophthalmology, 2011
The field of retinal prosthetic research, now more than 20 years old, has produced many high-quality technical options that have the potential to restore vision to patients with acquired disease of the outer retina. Five companies have performed Phase I clinical trials demonstrating that blind patients can reliably report basic elements of visual ...
J. Rizzo
openaire   +3 more sources

Long-term Follow-Up of Subjects in a Phase 1/2a Clinical Trial of Stem Cell-Derived Bioengineered Retinal Pigment Epithelium Implant for Geographic Atrophy.

Ophthalmology (Rochester, Minn.), 2023
PURPOSE To report long-term results from a Phase 1/2a clinical trial assessment of a scaffold-based human embryonic stem cell-derived retinal pigmented epithelium (RPE) implant in subjects with advanced geographic atrophy (GA).
M. Humayun, Dennis O. Clegg, Margot S. Dayan, Amir H. Kashani, Firas M. Rahhal, Robert L. Avery, H. Salehi-Had, Sanford Chen, C. Chan, Neal Palejwala, April D Ingram, Debbie Mitra, B. Pennington, C. Hinman, Mohamed A. Faynus, J. Bailey, Lincoln V. Johnson, Jane S. Lebkowski   +17 more
semanticscholar   +1 more source

Improved visual acuity using a retinal implant and an optimized stimulation strategy

Journal of Neural Engineering, 2019
Objective. Retinal prosthetic devices hold great promise for the treatment of retinal degenerative diseases such as retinitis pigmentosa and age-related macular degeneration.
Wei Tong, M. Stamp, N. Apollo, K. Ganesan, H. Meffin, S. Prawer, D. J. Garrett, M. Ibbotson   +7 more
semanticscholar   +1 more source

Microsensors and microbiosensors for retinal implants

Frontiers in Bioscience, 2005
This paper concentrates on recent developments in microsensors and microbiosensors for the possible applications in visual prostheses, especially retinal prosthetic devices. A brief introduction on the developments of visual prosthesis will be presented. The importance for in-vivo pH measurements as well as the need for an implantable pH sensor will be
David D, Zhou, Robert J, Greenberg
openaire   +2 more sources

COMPARISON OF INTRAVITREAL DEXAMETHASONE IMPLANT AND AFLIBERCEPT IN PATIENTS WITH TREATMENT-NAIVE DIABETIC MACULAR EDEMA WITH SEROUS RETINAL DETACHMENT.

Retina, 2020
PURPOSE To compare the efficacy and safety of intravitreal dexamethasone (DEX) implant versus aflibercept in patients with treatment-naive diabetic macular edema with inflammatory biomarkers.
Cemal Ozsaygılı, N. Duru
semanticscholar   +1 more source

Efficacy and safety of dexamethasone intravitreal implant in patients with retinal vein occlusion resistant to anti-VEGF therapy: a 12-month prospective study

Cutaneous and Ocular Toxicology, 2019
Purpose: To evaluate the safety and efficacy of repeated intravitreal dexamethasone implant (Ozurdex) injections administrated on an “as-needed” protocol for retinal vein occlusion patients with macular oedema, previously subjected to at least five anti ...
Lias Georgalas, Ioannis Tservakis, Eftychia Eleftheria Kiskira, P. Petrou, D. Papaconstantinou, Menelaos Kanakis   +5 more
semanticscholar   +1 more source

Ganciclovir implant in the treatment of cytomegalovirus retinitis

Expert Review of Medical Devices, 2005
The ganciclovir implant is a sustained-release intraocular drug delivery system used to treat cytomegalovirus retinitis that provides a high and steady-state concentration of the drug in the vitreous cavity over a period of 7-8 months. Randomized, controlled clinical trials have demonstrated a superior efficacy of the implant compared with intravenous ...
Margaret, Chang, James P, Dunn
openaire   +2 more sources